Ultragenyx Pharmaceutical Inc. (RARE) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Ultragenyx Pharmaceutical reported revenue of $673.0M, up 20.1% from $560.2M the year before. Net income was -$575.0M (a -85.4% net margin), or -$5.83 per diluted share. Operating margin was -79.5%. Operating activities generated -$466.0M of cash, leaving -$472.0M of free cash flow. At fiscal year end, Ultragenyx Pharmaceutical held $1.53B in total assets against $1.60B in total liabilities, including $421.0M of cash and equivalents.
Open the full interactive Ultragenyx Pharmaceutical financials → Quarterly statements, key ratios, valuation history and price charts.
Ultragenyx Pharmaceutical Key Stats
| Share Price | $14.92 |
|---|---|
| Market Cap | $1.52B |
| Revenue YoY Growth | +20.1% |
| 52-Week Range | $12.88 – $36.54 |
| Shares Outstanding | 101.9 million (basic, 2026 Q2) |
Ultragenyx Pharmaceutical Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $271.0M | $351.4M | $363.3M | $434.2M | $560.2M | $673.0M |
| Operating Income | -$330.1M | -$381.7M | -$648.9M | -$569.2M | -$536.0M | -$535.0M |
| Pre-Tax Income | -$185.4M | -$453.0M | -$701.7M | -$608.5M | -$567.6M | -$571.0M |
| Income Tax | $1.2M | $1.0M | $5.7M | -$1.8M | $1.6M | $4.0M |
| Net Income | -$186.6M | -$454.0M | -$707.4M | -$606.6M | -$569.2M | -$575.0M |
| Diluted EPS | -$0.37 | -$6.70 | -$10.12 | -$8.25 | -$6.29 | -$5.83 |
Ultragenyx Pharmaceutical Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $159.9M | $207.3M | $136.0M | $214.0M |
| Net Income | -$180.4M | -$128.6M | -$185.0M | -$92.0M |
| Diluted EPS | -$1.81 | -$1.30 | -$1.84 | -$0.90 |
Ultragenyx Pharmaceutical Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $713.5M | $307.6M | $132.9M | $213.6M | $173.7M | $421.0M |
| Current Assets | $1.30B | $856.6M | $883.9M | $732.2M | $817.1M | $951.0M |
| Total Assets | $1.76B | $1.52B | $1.55B | $1.49B | $1.50B | $1.53B |
| Current Liabilities | $189.6M | $181.4M | $261.2M | $280.4M | $344.2M | $384.0M |
| Total Liabilities | $605.2M | $599.8M | $1.19B | $1.22B | $1.24B | $1.60B |
| Shareholders' Equity | $1.15B | $922.6M | $352.5M | $275.4M | $255.3M | -$80.0M |
Ultragenyx Pharmaceutical Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$132.2M | -$338.7M | -$380.5M | -$474.8M | -$414.2M | -$466.0M |
| Cash From Investing | -$179.1M | -$195.4M | -$291.7M | $168.0M | -$17.8M | $236.0M |
| Cash From Financing | $600.3M | $118.6M | $501.2M | $388.1M | $399.2M | $478.0M |
| Free Cash Flow | -$176.1M | -$411.8M | -$496.6M | -$519.1M | -$421.7M | -$472.0M |
Figures from Ultragenyx Pharmaceutical's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Ultragenyx Pharmaceutical financials page for every line item.
Ultragenyx Pharmaceutical Company Profile
| Ticker | RARE |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Novato, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001515673 |
Frequently Asked Questions
What was Ultragenyx Pharmaceutical's revenue in fiscal 2025?
Ultragenyx Pharmaceutical (RARE) reported revenue of $673.0M for fiscal 2025.
What is Ultragenyx Pharmaceutical's annual revenue history?
Ultragenyx Pharmaceutical's annual revenue by fiscal year: 2020: $271.0M; 2021: $351.4M; 2022: $363.3M; 2023: $434.2M; 2024: $560.2M; 2025: $673.0M.
What was Ultragenyx Pharmaceutical's net income in fiscal 2025?
Ultragenyx Pharmaceutical reported net income of -$575.0M for fiscal 2025.
What was Ultragenyx Pharmaceutical's earnings per share (EPS) in fiscal 2025?
Ultragenyx Pharmaceutical's diluted EPS was -$5.83 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Ultragenyx Pharmaceutical generate in fiscal 2025?
Ultragenyx Pharmaceutical generated -$472.0M of free cash flow in fiscal 2025.
What was Ultragenyx Pharmaceutical's revenue last quarter?
In its most recent reported quarter (2026 Q2), Ultragenyx Pharmaceutical reported revenue of $214.0M.
How many shares of Ultragenyx Pharmaceutical are outstanding?
Ultragenyx Pharmaceutical reported a weighted average of 101.9 million basic shares outstanding in 2026 Q2.
What is Ultragenyx Pharmaceutical's market cap?
Based on its latest closing price, Ultragenyx Pharmaceutical (RARE) has a market capitalization of about $1.52B.
When does Ultragenyx Pharmaceutical's fiscal year end?
Ultragenyx Pharmaceutical's fiscal year end, as registered with the SEC, is December 31.
Where is Ultragenyx Pharmaceutical headquartered?
Ultragenyx Pharmaceutical lists its business address in Novato, California in its SEC filings.